Short Interest in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Increases By 31.4%

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRXGet Rating) was the recipient of a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 602,200 shares, an increase of 31.4% from the April 15th total of 458,300 shares. Based on an average daily trading volume, of 561,400 shares, the short-interest ratio is presently 1.1 days.

Several institutional investors and hedge funds have recently modified their holdings of SLRX. Morgan Stanley increased its holdings in shares of Salarius Pharmaceuticals by 30,613.5% in the 2nd quarter. Morgan Stanley now owns 490,802 shares of the company’s stock valued at $521,000 after purchasing an additional 489,204 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Salarius Pharmaceuticals in the 4th quarter valued at about $89,000. Two Sigma Advisers LP acquired a new position in shares of Salarius Pharmaceuticals in the 3rd quarter valued at about $114,000. Geode Capital Management LLC grew its stake in shares of Salarius Pharmaceuticals by 28.5% in the 3rd quarter. Geode Capital Management LLC now owns 356,114 shares of the company’s stock valued at $363,000 after buying an additional 79,079 shares in the last quarter. Finally, Citadel Advisors LLC grew its stake in shares of Salarius Pharmaceuticals by 502.7% in the 2nd quarter. Citadel Advisors LLC now owns 85,436 shares of the company’s stock valued at $91,000 after buying an additional 71,260 shares in the last quarter. Institutional investors own 11.38% of the company’s stock.

Several analysts have issued reports on the company. HC Wainwright cut their price objective on Salarius Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, March 11th. Zacks Investment Research upgraded Salarius Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, May 5th.

Shares of SLRX traded down $0.01 during trading hours on Monday, reaching $0.18. The company’s stock had a trading volume of 32,789 shares, compared to its average volume of 675,795. Salarius Pharmaceuticals has a 1-year low of $0.16 and a 1-year high of $1.51. The company has a 50 day moving average of $0.33 and a two-hundred day moving average of $0.48.

Salarius Pharmaceuticals (NASDAQ:SLRXGet Rating) last issued its earnings results on Thursday, March 10th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. During the same period last year, the company posted ($0.10) earnings per share. Equities research analysts expect that Salarius Pharmaceuticals will post -0.38 earnings per share for the current fiscal year.

Salarius Pharmaceuticals Company Profile (Get Rating)

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.

Featured Stories

Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.